Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scan may reveal Parkinson's before symptoms worsen

NCT ID NCT02488395

Diagnosis Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a brain scan (fMRI) can detect early signs of Parkinson's disease by looking at a part of the brain called the superior colliculus. Researchers compared newly diagnosed Parkinson's patients (not yet on medication) with healthy volunteers. The goal is to find a new way to diagnose Parkinson's earlier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this works, it could point toward a new way to diagnose Parkinson's disease earlier, before symptoms get worse.
What could go wrong
This is a very small, early study with only 23 people. It's looking for a brain signal, not testing a treatment, so it may not lead to a practical test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

23 people

The number who actually took part.

Started

Oct 2015

Finished

Jan 2018

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Groups of de novo Parkinson's patients and their age matching controls.

Ages

35 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * De novo parkinson's patients being just diagnosed (stage 1 according to the Hoehn and Yahr scale: first unilateral signs with no discomfort in everyday life) without a current dopaminergic treatment and who have not started their anti-parkinsonian treatment. * Both Parkinson's patients and their age matching control must not present a major visual pathology (mainly in the retina) which may interfere with the visual task. * Signed informed and free consent. * Matching controls must not present a neurological or psychiatric troubles. * For the matching controls: There are no contraindication on current treatments apart from those to treat other neurological disease than Parkinson's disease or psychiatric troubles. * For Parkinson's patients: There are no contraindication on current treatments apart from those to treat neurological troubles including anti-parkinsonian treatment, or psychiatric troubles. * As a precaution, the investigators will check that no MRI exam has been performed during the week preceding our fMRI. Exclusion Criteria: * Parkinson's patients with important tremor limiting the validity of the fMRI acquisition. * Adult under supervision * Incapacity to understand the consent explanations. * Impossibility to participate to the whole experimental protocol. * No affiliation to a health insurance. * Consent not signed by a participant or refusal by the participant to participate to the experiment. * Pregnancy or breast feeding woman. * Administrative or justice freedom restricted participant. Exclusion Criteria specific for MRI: * Pacemaker, neurosensorial stimulator or implanted defibrillator. * Presence of ocular or cerebral ferromagnetic material. * Respiratory disease (i.e. asthma), cardio-vascular deficits, claustrophobia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease

Contacts and locations

Locations

  • CHU de Grenoble

    Grenoble, Isere, 38000, France

  • Grenoble Institute of Neurosciences

    Grenoble, Isere, 38000, France

  • IRMAGE

    Grenoble, Isere, 38000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.